Shaomeng Wang

List of Publications by Year in Descending Order

354 papers	26,369 citations	87 h-index	147 g-index
529 ext. papers	29,365 ext. citations	7.5 avg, IF	6.87 L-index

#	Paper	IF	Citations
354	Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-X dual inhibitor that induces Bax-dependent apoptosis.. *Neoplasia*, **2022**, 29, 100798	6.4	0
353	The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells.. *American Journal of Cancer Research*, **2022**, 12, 779-792	4.4	
352	Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression. *Journal of Medicinal Chemistry*, **2021**, 64, 14540-14556	8.3	7
351	BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade. *Oncogene*, **2021**, 40, 6566-6578	9.2	2
350	Topography of transcriptionally active chromatin in glioblastoma. *Science Advances*, **2021**, 7,	14.3	4
349	SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression. *ACS Medicinal Chemistry Letters*, **2021**, 12, 996-1004	4.3	3
348	Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity. *Nature Communications*, **2021**, 12, 2621	17.4	1
347	Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression. *Journal of Medicinal Chemistry*, **2021**, 64, 10333-10349	8.3	3
346	Potency and Selectivity Optimization of Tryptophanol-Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer. *ChemMedChem*, **2021**, 16, 250-258	3.7	2
345	Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. *Clinical Cancer Research*, **2021**, 27, 2301-2313	12.9	7
344	The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. *Nature Immunology*, **2021**, 22, 460-470	19.1	11
343	Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer. *Journal of Medicinal Chemistry*, **2021**, 64, 12831-12854	8.3	14
342	Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. *Journal of Medicinal Chemistry* , **2021**, 64, 13487-13509	8.3	12
341	Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. *Journal of Medicinal Chemistry*, **2021**, 64, 14895-14911	8.3	6
340	Discovery of Potent Small-Molecule Inhibitors of MLL Methyltransferase. *ACS Medicinal Chemistry Letters*, **2020**, 11, 1348-1352	4.3	6
339	Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein. *Journal of Medicinal Chemistry*, **2020**, 63, 7510-7528	8.3	38
338	EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development. *Journal of Medicinal Chemistry*, **2020**, 63, 7252-7267	8.3	14

337	Confronting Racism in Chemistry Journals. *ACS Applied Nano Materials*, **2020**, 3, 6131-6133	5.6	
336	Confronting Racism in Chemistry Journals. *ACS Applied Polymer Materials*, **2020**, 2, 2496-2498	4.3	
335	Confronting Racism in Chemistry Journals. *Organometallics*, **2020**, 39, 2331-2333	3.8	
334	BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1. *Cancer Research*, **2020**, 80, 2380-2393	10.1	14
333	Update to Our Reader, Reviewer, and Author Communities April 2020. *Energy & Fuels*, **2020**, 34, 5107-5108	4.1	
332	Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong Antitumor Activity. *Journal of Medicinal Chemistry*, **2020**, 63, 4997-5010	8.3	13
331	Update to Our Reader, Reviewer, and Author Communities April 2020. *Organometallics*, **2020**, 39, 1665-1666	3.8	
330	Confronting Racism in Chemistry Journals. *Journal of Chemical Health and Safety*, **2020**, 27, 198-200	1.7	
329	Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway. *Advances in Experimental Medicine and Biology*, **2020**, 1217, 349-362	3.6	3
328	Targeted degradation of activating estrogen receptor ligand-binding domain mutations in human breast cancer. *Breast Cancer Research and Treatment*, **2020**, 180, 611-622	4.4	22
327	Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. *Neoplasia*, **2020**, 22, 111-119	6.4	58
326	A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo. *Neoplasia*, **2020**, 22, 522-532	6.4	19
325	Selectively Targeting Tropomyosin Receptor Kinase A (TRKA) via PROTACs. *Journal of Medicinal Chemistry*, **2020**, 63, 14560-14561	8.3	2
324	Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. *Journal of Medicinal Chemistry*, **2020**, 63, 13994-14016	8.3	7
323	Targeting transcriptional regulation of SARS-CoV-2 entry factors and. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**,	11.5	74
322	Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders. *Journal of Medicinal Chemistry*, **2019**, 62, 9471-9487	8.3	54
321	Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction. *Journal of Medicinal Chemistry*, **2019**, 62, 6015-6034	8.3	13
320	Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction. *Journal of Medicinal Chemistry*, **2019**, 62, 5382-5403	8.3	17

319	The Direct Molecular Target for Imipridone ONC201 Is Finally Established. *Cancer Cell*, **2019**, 35, 707-708	24.3	12
318	Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review. *Drug Discovery Today: Technologies*, **2019**, 31, 43-51	7.1	59
317	Chemical suppression of specific C-C chemokine signaling pathways enhances cardiac reprogramming. *Journal of Biological Chemistry*, **2019**, 294, 9134-9146	5.4	8
316	Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer. *Clinical Cancer Research*, **2019**, 25, 4038-4048	12.9	16
315	Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma. *Neoplasia*, **2019**, 21, 322-330	6.4	5
314	Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5- a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction. *Journal of Medicinal Chemistry*, **2019**, 62, 2772-2797	8.3	39
313	A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. *Cancer Cell*, **2019**, 36, 498-511.e17	24.3	181
312	Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR. *Journal of Clinical Investigation*, **2019**, 129, 1626-1640	15.9	16
311	Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein. *Journal of Medicinal Chemistry*, **2019**, 62, 11280-11300	8.3	75
310	Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. *Journal of Medicinal Chemistry*, **2019**, 62, 11218-11231	8.3	61
309	Casein kinase-1 and 3 stimulate tumor necrosis factor-induced necroptosis through RIPK3. *Cell Death and Disease*, **2019**, 10, 923	9.8	10
308	Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). *Journal of Medicinal Chemistry*, **2019**, 62, 1420-1442	8.3	106
307	Changing the Apoptosis Pathway through Evolutionary Protein Design. *Journal of Molecular Biology* , **2019**, 431, 825-841	6.5	12
306	Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. *Journal of Medicinal Chemistry*, **2019**, 62, 941-964	8.3	157
305	Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. *Journal of Medicinal Chemistry*, **2019**, 62, 448-466	8.3	132
304	Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. *Clinical Cancer Research*, **2019**, 25, 1588-1600	12.9	13
303	High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction. *Journal of Medicinal Chemistry*, **2018**, 61, 1934-1950	8.3	31
302	Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer. *Cell Reports*, **2018**, 22, 2236-2245	10.6	50

301	Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction. *Angewandte Chemie - International Edition*, **2018**, 57, 1601-1605	16.4	37
300	Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction. *Angewandte Chemie*, **2018**, 130, 1617-1621	3.6	1
299	Cyclic Peptidic Mimetics of Apollo Peptides Targeting Telomeric Repeat Binding Factor 2 (TRF2) and Apollo Interaction. *ACS Medicinal Chemistry Letters*, **2018**, 9, 507-511	4.3	5
298	Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. *Journal of Medicinal Chemistry*, **2018**, 61, 462-481	8.3	197
297	Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. *Journal of Medicinal Chemistry*, **2018**, 61, 6110-6120	8.3	15
296	Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. *Journal of Medicinal Chemistry*, **2018**, 61, 6685-6704	8.3	133
295	Induction of p53 suppresses chronic myeloid leukemia. *Leukemia and Lymphoma*, **2017**, 58, 1-14	1.9	7
294	Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. *Cancer Research*, **2017**, 77, 2476-2487	9.3	115
293	Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. *Cold Spring Harbor Perspectives in Medicine*, **2017**, 7,	5.4	137
292	Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED). *Journal of Medicinal Chemistry*, **2017**, 60, 2212-2214	8.3	8
291	Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. *Journal of Medicinal Chemistry*, **2017**, 60, 3887-3901	8.3	23
290	Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction. *Journal of Medicinal Chemistry*, **2017**, 60, 4818-4839	8.3	49
289	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. *Cancer Cell*, **2017**, 31, 532-548.e7	24.3	57
288	Discovery of 4-((3*R*,4*S*,5*R*)-6?-Chloro-4*R*(3-chloro-2-fluorophenyl)-1*R*ethyl-2?-oxodispiro[cyclohexane-1,2*R*pyrrolidine-3*R*3?-indoline-5 Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. *Journal of Medicinal Chemistry*, **2017**, 60, 2819-2839	8.3	95
287	A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination. *EMBO Journal*, **2017**, 36, 1243-1260	13	41
286	A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation. *Nature Communications*, **2017**, 8, 1150	17.4	48
285	Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. *Clinical Cancer Research*, **2017**, 23, 1036-1048	12.9	22
284	IAPs protect host target tissues from graft-versus-host disease in mice. *Blood Advances*, **2017**, 1, 1517-1532	7.8	11

283	Functional Analyses of BTK Mutations in Follicular Lymphoma. *Blood*, **2017**, 130, 647-647	2.2	
282	Targeting Inhibitor of Apoptosis Proteins Protects from Bleomycin-Induced Lung Fibrosis. *American Journal of Respiratory Cell and Molecular Biology*, **2016**, 54, 482-92	5.7	30
281	Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus. *European Journal of Medicinal Chemistry*, **2016**, 108, 229-244	6.8	35
280	Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer. *Molecular Cancer Therapeutics*, **2016**, 15, 2887-2893	6.1	20
279	Targeting Mll1 H3K4 methyltransferase activity to guide cardiac lineage specific reprogramming of fibroblasts. *Cell Discovery*, **2016**, 2, 16036	22.3	31
278	MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program. *Cell Discovery*, **2016**, 2, 16008	22.3	24
277	Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma. *Clinical Cancer Research*, **2016**, 22, 5383-5393	12.9	23
276	A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. *Investigational New Drugs*, **2016**, 34, 481-9	4.3	22
275	BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. *Molecular Cancer Research*, **2016**, 14, 324-31	6.6	120
274	Design of High-Affinity Stapled Peptides To Target the Repressor Activator Protein 1 (RAP1)/Telomeric Repeat-Binding Factor 2 (TRF2) Protein-Protein Interaction in the Shelterin Complex. *Journal of Medicinal Chemistry*, **2016**, 59, 328-34	8.3	15
273	Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells. *Neoplasia*, **2016**, 18, 162-71	6.4	44
272	MLL1 Inhibition Reprograms Epiblast Stem Cells to Naive Pluripotency. *Cell Stem Cell*, **2016**, 18, 481-94	18	38
271	Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. *Clinical Cancer Research*, **2016**, 22, 3550-9	12.9	10
270	Functional Analyses of V-Atpase Mutations in Follicular Lymphoma. *Blood*, **2016**, 128, 1762-1762	2.2	
269	Inducing Protein Degradation as a Therapeutic Strategy. *Journal of Medicinal Chemistry*, **2016**, 59, 5129-30	8.3	6
268	MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. *Neoplasia*, **2016**, 18, 213-22	6.4	33
267	Role of BET proteins in castration-resistant prostate cancer. *Drug Discovery Today: Technologies*, **2016**, 19, 29-38	7.1	12
266	BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma. *Oral Oncology*, **2015**, 51, 839-47	4.4	10

265	Structure-Based Design of β-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors. *Journal of Medicinal Chemistry*, **2015**, 58, 4927-39	8.3	66
264	BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. *Blood*, **2015**, 125, 2724-8	2.2	30
263	Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo. *Clinical Cancer Research*, **2015**, 21, 2558-68	12.9	36
262	Structure-based design of conformationally constrained cyclic peptidomimetics to target the MLL1-WDR5 protein–protein interaction as inhibitors of the MLL1 methyltransferase activity. *Chinese Chemical Letters*, **2015**, 26, 455-458	8.1	4
261	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. *Journal of Medicinal Chemistry*, **2015**, 58, 1038-52	8.3	314
260	Activating STAT6 mutations in follicular lymphoma. *Blood*, **2015**, 125, 668-79	2.2	87
259	Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment. *PLoS ONE*, **2015**, 10, e0128807	3.7	19
258	SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells. *Oncotarget*, **2015**, 6, 37410-25	3.3	15
257	Case Study: discovery of inhibitors of the MDM2-p53 protein-protein interaction. *Methods in Molecular Biology*, **2015**, 1278, 567-85	1.4	3
256	Analysis of 54 Follicular Lymphomas By Whole Exome Sequencing Identifies Multiple Novel Recurrently Mutated Pathways. *Blood*, **2015**, 126, 112-112	2.2	
255	Targeting apoptosis pathways for new cancer therapeutics. *Annual Review of Medicine*, **2014**, 65, 139-55	17.4	129
254	Pramipexole derivatives as potent and selective dopamine D(3) receptor agonists with improved human microsomal stability. *ChemMedChem*, **2014**, 9, 2653-60	3.7	8
253	SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. *Cancer Research*, **2014**, 74, 5855-65	10.1	205
252	Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D₃ receptor antagonists. *Journal of Medicinal Chemistry*, **2014**, 57, 4962-8	8.3	35
251	Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells. *ACS Chemical Biology*, **2014**, 9, 994-1002	4.9	26
250	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. *Nature* , **2014**, 510, 278-82	50.4	650
249	Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. *Molecular Cell*, **2014**, 53, 247-61	17.6	203
248	Small-molecule SMAC mimetics as new cancer therapeutics. *Pharmacology & Therapeutics*, **2014**, 144, 82-95	13.9	118

247	Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles. *Journal of Medicinal Chemistry*, **2014**, 57, 10486-98	8.3	47
246	BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. *PLoS ONE*, **2014**, 9, e99404	3.7	61
245	Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. *Biopharmaceutics and Drug Disposition*, **2013**, 34, 348-59	1.7	15
244	LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. *Journal of Medicinal Chemistry*, **2013**, 56, 5673-4	8.3	41
243	Optimization and validation of mitochondria-based functional assay as a useful tool to identify BH3-like molecules selectively targeting anti-apoptotic Bcl-2 proteins. *BMC Biotechnology*, **2013**, 13, 45	3.5	5
242	RNF111-dependent neddylation activates DNA damage-induced ubiquitination. *Molecular Cell*, **2013**, 49, 897-907	17.6	93
241	Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. *Journal of Medicinal Chemistry*, **2013**, 56, 1113-23	8.3	71
240	High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. *Journal of the American Chemical Society*, **2013**, 135, 669-82	16.4	117
239	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. *Cell Reports*, **2013**, 4, 1116-30	10.6	447
238	A potent and highly efficacious Bcl-2/Bcl-xL inhibitor. *Journal of Medicinal Chemistry*, **2013**, 56, 3048-3067	8.3	31
237	Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. *Journal of the American Chemical Society*, **2013**, 135, 7223-34	16.4	165
236	A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. *Journal of Medicinal Chemistry*, **2013**, 56, 5553-61	8.3	196
235	A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. *Science Signaling*, **2013**, 6, ra32	8.8	44
234	A sequence variant in the phospholipase C epsilon C2 domain is associated with esophageal carcinoma and esophagitis. *Molecular Carcinogenesis*, **2013**, 52 Suppl 1, E80-6	5	13
233	A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice. *Journal of Medicinal Chemistry*, **2013**, 56, 3969-79	8.3	29
232	The making of I-BET762, a BET bromodomain inhibitor now in clinical development. *Journal of Medicinal Chemistry*, **2013**, 56, 7498-500	8.3	65
231	Identification of a mutant α1 Na/K-ATPase that pumps but is defective in signal transduction. *Journal of Biological Chemistry*, **2013**, 288, 13295-304	5.4	46
230	The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response. *Genes and Development*, **2013**, 27, 1752-68	12.6	107

229	Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants. *Angewandte Chemie - International Edition*, **2013**, 52, 8387-90	16.4	25
228	Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats. *Psychopharmacology*, **2012**, 219, 123-35	4.7	19
227	p53-mediated heterochromatin reorganization regulates its cell fate decisions. *Nature Structural and Molecular Biology*, **2012**, 19, 478-84, S1	17.6	41
226	cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation. *Cell Death and Differentiation*, **2012**, 19, 1791-801	12.7	105
225	Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics. *Journal of Mammary Gland Biology and Neoplasia*, **2012**, 17, 217-28	2.4	33
224	Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression. *Journal of Medicinal Chemistry*, **2012**, 55, 8502-14	8.3	44
223	High-affinity and selective dopamine D□ receptor full agonists. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 5612-7	2.9	11
222	Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold. *Journal of Medicinal Chemistry*, **2012**, 55, 4664-82	8.3	55
221	AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. *Cancer Biology and Therapy*, **2012**, 13, 804-11	4.6	43
220	Analysis of Flexibility and Hotspots in Bcl-xL and Mcl-1 Proteins for the Design of Selective Small-Molecule Inhibitors. *ACS Medicinal Chemistry Letters*, **2012**, 3, 308-12	4.3	30
219	Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents. *Journal of Medicinal Chemistry*, **2012**, 55, 106-14	8.3	29
218	Design of triazole-stapled BCL9 □helical peptides to target the □catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction. *Journal of Medicinal Chemistry*, **2012**, 55, 1137-46	8.3	195
217	Hepatic TRAF2 regulates glucose metabolism through enhancing glucagon responses. *Diabetes*, **2012**, 61, 566-73	0.9	41
216	Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics. *Topics in Medicinal Chemistry*, **2012**, 57-79	0.4	51
215	Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis. *Breast Cancer Research and Treatment*, **2012**, 133, 189-99	4.4	25
214	AM-8553: a novel MDM2 inhibitor with a promising outlook for potential clinical development. *Journal of Medicinal Chemistry*, **2012**, 55, 4934-5	8.3	28
213	Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity. *Journal of Medicinal Chemistry*, **2012**, 55, 6149-61	8.3	43
212	LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNF□expression and receptor tyrosine kinase signaling. *Cancer Research*, **2012**, 72, 1229-38	10.1	31

211	Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. *Cancer Research*, **2012**, 72, 716-25	10.1	14
210	A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. *Journal of Medicinal Chemistry*, **2011**, 54, 2714-26	8.3	207
209	Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity. *Journal of Medicinal Chemistry*, **2011**, 54, 3306-18	8.3	38
208	Hydrophobic Binding Hot Spots of Bcl-xL Protein-Protein Interfaces by Cosolvent Molecular Dynamics Simulation. *ACS Medicinal Chemistry Letters*, **2011**, 2, 280-4	4.3	45
207	CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist. *ACS Medicinal Chemistry Letters*, **2011**, 2, 620-625	4.3	15
206	Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D3 and D2 receptor sensitivity. *Psychopharmacology*, **2011**, 215, 609-20	4.7	26
205	Design of small-molecule Smac mimetics as IAP antagonists. *Current Topics in Microbiology and Immunology*, **2011**, 348, 89-113	3.3	47
204	CSAR benchmark exercise of 2010: selection of the protein-ligand complexes. *Journal of Chemical Information and Modeling*, **2011**, 51, 2036-46	6.1	102
203	Correction to CSAR Benchmark Exercise of 2010: Selection of the Protein□ligand Complexes. *Journal of Chemical Information and Modeling*, **2011**, 51, 2146-2146	6.1	4
202	CSAR benchmark exercise of 2010: combined evaluation across all submitted scoring functions. *Journal of Chemical Information and Modeling*, **2011**, 51, 2115-31	6.1	117
201	Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases. *Molecular Cancer Therapeutics*, **2011**, 10, 658-69	6.1	36
200	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes. *Drug Metabolism and Disposition*, **2011**, 39, 627-35	4	10
199	Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. *Molecular Cancer Therapeutics*, **2011**, 10, 902-14	6.1	59
198	A dual-readout F2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions. *Assay and Drug Development Technologies*, **2011**, 9, 382-93	2.1	15
197	Abstract LB-204: Highly potent and optimized small-molecule inhibitors of MDM2 achieve complete tumor regression in animal models of solid tumors and leukemia. **2011**,		3
196	Case Study: Inhibitors of the MDM2-p53 Protein□Protein Interaction **2010**, 273-293		
195	Smac mimetic compounds potentiate interleukin-1beta-mediated cell death. *Journal of Biological Chemistry*, **2010**, 285, 40612-23	5.4	19
194	Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions. *Journal of Biological Chemistry*, **2010**, 285, 21023-36	5.4	30

193	Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. *Journal of Medicinal Chemistry*, **2010**, 53, 5179-85	8.3	50
192	Computational analysis of protein hotspots. *ACS Medicinal Chemistry Letters*, **2010**, 1, 125-9	4.3	24
191	MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. *European Journal of Cancer*, **2010**, 46, 1122-31	7.5	54
190	Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors. *ACS Medicinal Chemistry Letters*, **2010**, 1, 85-89	4.3	74
189	Superparamagnetic iron oxide nanotheranostics for targeted cancer cell imaging and pH-dependent intracellular drug release. *Molecular Pharmaceutics*, **2010**, 7, 1974-84	5.6	110
188	Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. *Journal of Medicinal Chemistry*, **2010**, 53, 6361-7	8.3	39
187	Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. *Blood*, **2010**, 116, 71-80	2.2	75
186	AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. *Journal of Cellular Biochemistry*, **2010**, 110, 1187-94	4.7	19
185	Cyclopeptide Smac mimetics as antagonists of IAP proteins. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 3043-6	2.9	31
184	Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation. *International Journal of Radiation Oncology Biology Physics*, **2010**, 78, 879-87	4	12
183	Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. *Journal of Pharmacology and Experimental Therapeutics*, **2009**, 329, 210-7	4.7	39
182	TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. *Cancer Research*, **2009**, 69, 2757-65	10.1	71
181	Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition. *Cancer Research*, **2009**, 69, 6556-64	10.1	80
180	TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. *Molecular Cancer Therapeutics*, **2009**, 8, 893-903	6.1	45
179	Efficient synthesis of phosphotyrosine building blocks using imidazolium trifluoroacetate. *Tetrahedron Letters*, **2009**, 50, 6691-6692	2	6
178	Design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 1733-6	2.9	22
177	Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases. *Journal of Medicinal Chemistry*, **2009**, 52, 593-6	8.3	38
176	Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction. *Biochemistry*, **2009**, 48, 9534-41	3.2	30

175	Importance of ligand reorganization free energy in protein-ligand binding-affinity prediction. *Journal of the American Chemical Society*, **2009**, 131, 13709-21	16.4	59
174	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. *Annual Review of Pharmacology and Toxicology*, **2009**, 49, 223-41	17.9	477
173	An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. *Molecular Cancer*, **2009**, 8, 115	42.1	57
172	Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. *Journal of Medicinal Chemistry*, **2009**, 52, 7970-3	8.3	150
171	Dopamine D2/3 receptor partial agonists failed to produce antidepressant-like effects in the rat forced swim test. *FASEB Journal*, **2009**, 23, 745.6	0.9	
170	-(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro. *Pharmacological Research*, **2008**, 58, 323-31	10.2	33
169	Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. *Molecular Cancer*, **2008**, 7, 20	42.1	60
168	Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). *Journal of Medicinal Chemistry*, **2008**, 51, 7169-80	8.3	72
167	Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases. *Journal of Medicinal Chemistry*, **2008**, 51, 7352-5	8.3	34
166	Targeting the MDM2-p53 interaction for cancer therapy. *Clinical Cancer Research*, **2008**, 14, 5318-24	12.9	248
165	Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. *Molecular Cancer Therapeutics*, **2008**, 7, 1772-81	6.1	160
164	Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. *Blood*, **2008**, 111, 1584-93	2.2	103
163	Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile. *Journal of Medicinal Chemistry*, **2008**, 51, 5905-8	8.3	27
162	Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. *Journal of Medicinal Chemistry*, **2008**, 51, 717-20	8.3	67
161	Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases. *Journal of Medicinal Chemistry*, **2008**, 51, 8158-62	8.3	45
160	Interaction of a cyclic, bivalent smac mimetic with the x-linked inhibitor of apoptosis protein. *Biochemistry*, **2008**, 47, 9811-24	3.2	48
159	A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy. *Cancer Biology and Therapy*, **2008**, 7, 845-52	4.6	27
158	The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis. *Cell Cycle*, **2008**, 7, 971-9	4.7	24

157	Anti-oxidant treatment enhances anti-tumor cytotoxicity of (-)-gossypol. *Cancer Biology and Therapy*, **2008**, 7, 767-76	4.6	14
156	Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. *Cancer Biology and Therapy*, **2008**, 7, 1418-26	4.6	38
155	Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 3933-8	11.5	574
154	Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. *Molecular Cancer Therapeutics*, **2008**, 7, 1533-42	6.1	69
153	Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. *Molecular Pharmacology*, **2008**, 73, 1632-42	4.3	61
152	Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. *Molecular Cancer Therapeutics*, **2008**, 7, 2884-93	6.1	35
151	SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. *Cancer Research*, **2008**, 68, 9384-93	10.1	155
150	TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. *International Journal of Cancer*, **2008**, 123, 958-66	7.5	47
149	Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. *Analytical Biochemistry*, **2008**, 374, 87-98	3.1	42
148	Design of small-molecule peptidic and nonpeptidic Smac mimetics. *Accounts of Chemical Research*, **2008**, 41, 1264-77	24.3	124
147	Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. *Journal of Medicinal Chemistry*, **2007**, 50, 1723-6	8.3	40
146	Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. *Journal of the American Chemical Society*, **2007**, 129, 15279-94	16.4	175
145	Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins. *Journal of Medicinal Chemistry*, **2007**, 50, 3163-6	8.3	36
144	(alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. *Journal of the American Chemical Society*, **2007**, 129, 139-54	16.4	156
143	Design and synthesis of a new, conformationally constrained, macrocyclic small-molecule inhibitor of STAT3 via ℟click chemistry℟. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 3939-42	2.9	50
142	Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP). *Biochemical Pharmacology*, **2007**, 73, 15-24	6	14
141	Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. *Psychopharmacology*, **2007**, 193, 159-70	4.7	107
140	A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells. *Annals of Hematology*, **2007**, 86, 471-81	3	13

139	p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway. *Cancer Biology and Therapy*, **2007**, 6, 360-6	4.6	7
138	Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. *Clinical Cancer Research* , **2007**, 13, 2226-35	12.9	135
137	Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellipticinium acetate (CMEP) in breast cancer cells. *Cancer Letters*, **2007**, 252, 244-58	9.9	9
136	Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. *Journal of the American Chemical Society*, **2007**, 129, 12809-14	16.4	119
135	Analysis of ligand-bound water molecules in high-resolution crystal structures of protein-ligand complexes. *Journal of Chemical Information and Modeling*, **2007**, 47, 668-75	6.1	134
134	Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.. *Blood*, **2007**, 110, 224-224	2.2	
133	Evaluation of TW-37, a pan Bcl-2 Proteins Small-Molecule Inhibitor, Against Spectrum of Human B-Cell Lines and Patient-Derived Samples.. *Blood*, **2007**, 110, 4521-4521	2.2	
132	A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. *Gynecologic Oncology*, **2006**, 100, 308-17	4.9	34
131	A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. *Cancer Research*, **2006**, 66, 11348-59	10.1	130
130	Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. *Cancer Research*, **2006**, 66, 8698-706	10.1	73
129	Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. *Clinical Cancer Research*, **2006**, 12, 4119-26	12.9	177
128	Identification of the fibroblast growth factor (FGF)-interacting domain in a secreted FGF-binding protein by phage display. *Journal of Biological Chemistry*, **2006**, 281, 1137-44	5.4	27
127	Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. *Journal of Medicinal Chemistry*, **2006**, 49, 7916-20	8.3	93
126	Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes. *Journal of the American Chemical Society*, **2006**, 128, 11830-9	16.4	80
125	Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. *Journal of Medicinal Chemistry*, **2006**, 49, 6139-42	8.3	257
124	Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. *Journal of Medicinal Chemistry*, **2006**, 49, 3759-62	8.3	117
123	M-score: a knowledge-based potential scoring function accounting for protein atom mobility. *Journal of Medicinal Chemistry*, **2006**, 49, 5903-11	8.3	62
122	(-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. *Neoplasia*, **2006**, 8, 163-72	6.4	84

121	Computational elucidation of the structural basis of ligand binding to the dopamine 3 receptor through docking and homology modeling. *Journal of Medicinal Chemistry*, **2006**, 49, 4470-6	8.3	21
120	Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. *Journal of Medicinal Chemistry*, **2006**, 49, 3432-5	8.3	581
119	Chapter 11 Recent Advances in Design of Small-Molecule Ligands to Target Protein–Protein Interactions. *Annual Reports in Computational Chemistry*, **2006**, 197-219	1.8	1
118	Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 443-6	2.9	23
117	Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 5805-8	2.9	60
116	Design and synthesis of a 1,5-diazabicyclo[6,3,0] dodecane amino acid derivative as a novel dipeptide reverse-turn mimetic. *Tetrahedron Letters*, **2006**, 47, 4769-4770	2	10
115	Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3-substituted tyrosine derivatives. *Journal of Medicinal Chemistry*, **2006**, 49, 1585-96	8.3	38
114	The PDBbind database: methodologies and updates. *Journal of Medicinal Chemistry*, **2005**, 48, 4111-9	8.3	462
113	Chimeric (alpha/beta + alpha)-peptide ligands for the BH3-recognition cleft of Bcl-XL: critical role of the molecular scaffold in protein surface recognition. *Journal of the American Chemical Society*, **2005**, 127, 11966-8	16.4	161
112	Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. *Molecular Cancer Therapeutics*, **2005**, 4, 1096-104	6.1	109
111	Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands. *Journal of Medicinal Chemistry*, **2005**, 48, 3171-81	8.3	24
110	Structure-based design of potent non-peptide MDM2 inhibitors. *Journal of the American Chemical Society*, **2005**, 127, 10130-1	16.4	543
109	CHMIS-C: a comprehensive herbal medicine information system for cancer. *Journal of Medicinal Chemistry*, **2005**, 48, 1481-8	8.3	40
108	A systematic analysis of the effect of small-molecule binding on protein flexibility of the ligand-binding sites. *Journal of Medicinal Chemistry*, **2005**, 48, 5648-50	8.3	15
107	Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. *Pancreas*, **2005**, 31, 317-24	2.6	53
106	Efficient synthesis of isoflavone analogues via a Suzuki coupling reaction. *Tetrahedron Letters*, **2005**, 46, 3707-3709	2	24
105	Synthesis of spirooxindoles via asymmetric 1,3-dipolar cycloaddition. *Tetrahedron Letters*, **2005**, 46, 5949-5951	2	51
104	Design and synthesis of a potent biotinylated Smac mimetic. *Tetrahedron Letters*, **2005**, 46, 7015-7018	2	2

103	Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 793-7	2.9	48
102	Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 1701-5	2.9	19
101	Identification of novel neuroprotective agents using pharmacophore modeling. *Chemistry and Biodiversity*, **2005**, 2, 1564-70	2.5	5
100	A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 4700-5	11.5	412
99	Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. *Cancer Research*, **2005**, 65, 5063-9	10.1	91
98	Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. *Molecular Cancer Therapeutics*, **2005**, 4, 13-21	6.1	65
97	(-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. *Molecular Cancer Therapeutics*, **2005**, 4, 23-31	6.1	54
96	(-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. *Molecular Cancer Therapeutics*, **2005**, 4, 197-205	6.1	87
95	Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. *Cancer Research*, **2004**, 64, 7947-53	10.1	79
94	In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. *Clinical Cancer Research*, **2004**, 10, 7757-63	12.9	109
93	An efficient synthesis of optically pure (S)-2-functionalized 1,2,3,4-tetrahydroquinoline. *Tetrahedron Letters*, **2004**, 45, 1027-1029	2	6
92	Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. *Analytical Biochemistry*, **2004**, 332, 261-73	3.1	400
91	Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 5813-6	2.9	6
90	Solution Conformations of Wild-Type and Mutated Bak BH3 Peptides via Dynamical Conformational Sampling and Implication to Their Binding to Antiapoptotic Bcl-2 Proteins. *Journal of Physical Chemistry B*, **2004**, 108, 1467-1477	3.4	6
89	Formation of a novel reversible cytochrome P450 spectral intermediate: role of threonine 303 in P450 2E1 inactivation. *Biochemistry*, **2004**, 43, 11942-52	3.2	17
88	Structure-based discovery of nonpeptidic small organic compounds to block the T cell response to myelin basic protein. *Journal of Medicinal Chemistry*, **2004**, 47, 4989-97	8.3	31
87	Structure-based design of potent, conformationally constrained Smac mimetics. *Journal of the American Chemical Society*, **2004**, 126, 16686-7	16.4	143
86	Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. *Journal of Medicinal Chemistry*, **2004**, 47, 4147-50	8.3	131

85	Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. *Journal of Medicinal Chemistry*, **2004**, 47, 2430-40	8.3	313
84	Web-based tools for mining the NCI databases for anticancer drug discovery. *Journal of Chemical Information and Computer Sciences*, **2004**, 44, 249-57		25
83	An extensive test of 14 scoring functions using the PDBbind refined set of 800 protein-ligand complexes. *Journal of Chemical Information and Computer Sciences*, **2004**, 44, 2114-25		215
82	The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. *Journal of Medicinal Chemistry*, **2004**, 47, 2977-80	8.3	577
81	Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. *Seminars in Oncology*, **2003**, 30, 133-42	5.5	150
80	Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. *Biochemical Pharmacology*, **2003**, 66, 93-103	6	140
79	Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 513-7	2.9	72
78	2,3-Disubstituted quinuclidines as a novel class of dopamine transporter inhibitors. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 1123-36	3.4	6
77	Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. *Journal of Medicinal Chemistry*, **2003**, 46, 4377-92	8.3	134
76	Comparative evaluation of 11 scoring functions for molecular docking. *Journal of Medicinal Chemistry*, **2003**, 46, 2287-303	8.3	749
75	Discovery of substituted 3,4-diphenyl-thiazoles as a novel class of monoamine transporter inhibitors through 3-D pharmacophore search using a new pharmacophore model derived from mazindol. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 1775-8	2.9	13
74	Further development and validation of empirical scoring functions for structure-based binding affinity prediction. *Journal of Computer-Aided Molecular Design*, **2002**, 16, 11-26	4.2	842
73	Structural basis of RasGRP binding to high-affinity PKC ligands. *Journal of Medicinal Chemistry*, **2002** , 45, 853-60	8.3	21
72	Competitive and Reversible Binding of a Guest Molecule to Its Host in Aqueous Solution through Molecular Dynamics Simulation: Benzyl Alcohol/Cyclodextrin System. *Journal of Physical Chemistry B*, **2002**, 106, 4863-4872	3.4	37
71	A web-based 3D-database pharmacophore searching tool for drug discovery. *Journal of Chemical Information and Computer Sciences*, **2002**, 42, 192-8		22
70	Molecular modeling of the interactions of glutamate carboxypeptidase II with its potent NAAG-based inhibitors. *Journal of Medicinal Chemistry*, **2002**, 45, 4140-52	8.3	35
69	Direct observation of the folding and unfolding of a beta-hairpin in explicit water through computer simulation. *Journal of the American Chemical Society*, **2002**, 124, 5282-3	16.4	62
68	Pharmacophore-based discovery, synthesis, and biological evaluation of 4-phenyl-1-arylalkyl piperidines as dopamine transporter inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 495-500	2.9	22

67	Rational design, synthesis, and biological evaluation of rigid pyrrolidone analogues as potential inhibitors of prostate cancer cell growth. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 955-9	2.9	28
66	Pharmacophore-based discovery of 3,4-disubstituted pyrrolidines as a novel class of monoamine transporter inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 1113-8	2.9	45
65	Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 2515-9	2.9	77
64	Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase. *Journal of Medicinal Chemistry*, **2001**, 44, 1349-55	8.3	73
63	Molecular modeling, structure--activity relationships and functional antagonism studies of 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketones as a novel class of dopamine transporter inhibitors. *Bioorganic and Medicinal Chemistry*, **2001**, 9, 1753-64	3.4	18
62	Phorbol esters and related analogs regulate the subcellular localization of beta 2-chimaerin, a non-protein kinase C phorbol ester receptor. *Journal of Biological Chemistry*, **2001**, 276, 18303-12	5.4	59
61	Role of hydrophobic residues in the C1b domain of protein kinase C delta on ligand and phospholipid interactions. *Journal of Biological Chemistry*, **2001**, 276, 19580-7	5.4	41
60	How does consensus scoring work for virtual library screening? An idealized computer experiment. *Journal of Chemical Information and Computer Sciences*, **2001**, 41, 1422-6		236
59	Comparison of the NCI open database with seven large chemical structural databases. *Journal of Chemical Information and Computer Sciences*, **2001**, 41, 702-12		179
58	Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. *Journal of Medicinal Chemistry*, **2001**, 44, 4313-24	8.3	306
57	Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis. *Journal of Medicinal Chemistry*, **2001**, 44, 1690-701	8.3	42
56	Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides. *Journal of Medicinal Chemistry*, **2001**, 44, 898-908	8.3	46
55	Iridals are a novel class of ligands for phorbol ester receptors with modest selectivity for the RasGRP receptor subfamily. *Journal of Medicinal Chemistry*, **2001**, 44, 3872-80	8.3	37
54	Helix Folding of an Alanine-Based Peptide in Explicit Water. *Journal of Physical Chemistry B*, **2001**, 105, 2227-2235	3.4	49
53	Bicyclic Peptide Inhibitors of an Epithelial Cell-Derived Transmembrane Protease, Matriptase **2001**, 561-562		
52	Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies. *Journal of Medicinal Chemistry*, **2000**, 43, 351-60	8.3	65
51	Application of a Molecular Dynamics Simulation Method with a Generalized Effective Potential to the Flexible Molecular Docking Problems. *Journal of Physical Chemistry B*, **2000**, 104, 354-359	3.4	57
50	Folding Studies of a Linear Pentamer Peptide Adopting a Reverse Turn Conformation in Aqueous Solution through Molecular Dynamics Simulation. *Journal of Physical Chemistry B*, **2000**, 104, 8023-8034	3.4	27

49	3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. *Journal of Medicinal Chemistry*, **2000**, 43, 3045-51	8.3	187
48	Enhancing systematic motion in molecular dynamics simulation. *Journal of Chemical Physics*, **1999**, 110, 9401-9410	3.9	59
47	Folding of a 16-residue helical peptide using molecular dynamics simulation with Tsallis effective potential. *Journal of Chemical Physics*, **1999**, 111, 4359-4361	3.9	36
46	beta2-chimaerin is a novel target for diacylglycerol: binding properties and changes in subcellular localization mediated by ligand binding to its C1 domain. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 11854-9	11.5	89
45	Synthesis and protein kinase C binding activity of benzolactam-V7. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 1371-4	2.9	23
44	Synthesis of 8-Oxa analogues of norcocaine endowed with interesting cocaine-like activity. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 1831-6	2.9	12
43	MCDOCK: a Monte Carlo simulation approach to the molecular docking problem. *Journal of Computer-Aided Molecular Design*, **1999**, 13, 435-51	4.2	117
42	The transition from a pharmacophore-guided approach to a receptor-guided approach in the design of potent protein kinase C ligands **1999**, 82, 251-61		33
41	Probing the binding of indolactam-V to protein kinase C through site-directed mutagenesis and computational docking simulations. *Journal of Medicinal Chemistry*, **1999**, 42, 3436-46	8.3	23
40	Recognition and interaction of small rings with the ricin A-chain binding site. *Proteins: Structure, Function and Bioinformatics*, **1998**, 31, 33-41	4.2	28
39	Synthesis and anticholinesterase activity of huperzine A analogues containing phenol and catechol replacements for the pyridone ring. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 1413-8	2.9	32
38	Conformationally constrained analogues of diacylglycerol (DAG). 14. Dissection of the roles of the sn-1 and sn-2 carbonyls in DAG mimetics by isopharmacophore replacement. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 1757-62	2.9	16
37	Conformationally constrained analogues of diacylglycerol (DAG). 15. The indispensable role of the sn-1 and sn-2 carbonyls in the binding of DAG-lactones to protein kinase C (PK-C). *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 3403-8	2.9	20
36	Structure-based design and synthesis of small molecule protein-tyrosine phosphatase 1B inhibitors. *Bioorganic and Medicinal Chemistry*, **1998**, 6, 1799-810	3.4	49
35	Structure-Based Design of a New Class of Protein Kinase C Modulators. *Journal of the American Chemical Society*, **1998**, 120, 6629-6630	16.4	34
34	Self-Guided Molecular Dynamics Simulation for Efficient Conformational Search. *Journal of Physical Chemistry B*, **1998**, 102, 7238-7250	3.4	96
33	Synthesis and biology of the conformationally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I, a potent mGluR agonist. *Journal of Medicinal Chemistry*, **1998**, 41, 1641-50	8.3	62
32	Characterization of C-10 Substituted Analogues of Huperzine A as Inhibitors of Cholinesterases. *Advances in Behavioral Biology*, **1998**, 601-605		

31	Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain. *Journal of Biological Chemistry*, **1997**, 272, 29046-52	5.4	89
30	Hydrazide-containing inhibitors of HIV-1 integrase. *Journal of Medicinal Chemistry*, **1997**, 40, 937-41	8.3	97
29	Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity. *Journal of Medicinal Chemistry*, **1997**, 40, 1316-26	8.3	65
28	Coumarin-based inhibitors of HIV integrase. *Journal of Medicinal Chemistry*, **1997**, 40, 242-9	8.3	255
27	Discovery of HIV-1 integrase inhibitors by pharmacophore searching. *Journal of Medicinal Chemistry* , **1997**, 40, 930-6	8.3	117
26	Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. *Journal of Medicinal Chemistry*, **1997**, 40, 942-51	8.3	199
25	Synthesis, molecular modeling, and biology of the 1-benzyl derivative of APDC-an apparent mGluR6 selective ligand. *Bioorganic and Medicinal Chemistry Letters*, **1997**, 7, 601-606	2.9	49
24	Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. *Journal of Medicinal Chemistry*, **1996**, 39, 2472-81	8.3	146
23	Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching. *Journal of Medicinal Chemistry*, **1996**, 39, 2047-54	8.3	119
22	Identification of a More Potent Analogue of the Naturally Occurring Alkaloid Huperzine A. Predictive Molecular Modeling of Its Interaction with AChE. *Journal of the American Chemical Society*, **1996**, 118, 11357-11362	16.4	93
21	Molecular modeling and site-directed mutagenesis studies of a phorbol ester-binding site in protein kinase C. *Journal of Medicinal Chemistry*, **1996**, 39, 2541-53	8.3	44
20	Conformationally constrained analogues of diacylglycerol. 10. Ultrapotent protein kinase C ligands based on a racemic 5-disubstituted tetrahydro-2-furanone template. *Journal of Medicinal Chemistry*, **1996**, 39, 19-28	8.3	41
19	Molecular modeling in the discovery of drug leads. *Journal of Chemical Information and Computer Sciences*, **1996**, 36, 726-30		11
18	Conformationally constrained analogues of diacylglycerol. 12. Ultrapotent protein kinase C ligands based on a chiral 4,4-disubstituted heptono-1,4-lactone template. *Journal of Medicinal Chemistry*, **1996**, 39, 36-45	8.3	34
17	Conformationally constrained analogues of diacylglycerol. 11. Ultrapotent protein kinase C ligands based on a chiral 5-disubstituted tetrahydro-2-furanone template. *Journal of Medicinal Chemistry*, **1996**, 39, 29-35	8.3	35
16	Synthesis and biology of the rigidified glutamate analogue, trans-2-carboxyazetidine-3-acetic acid (t-CAA). *Bioorganic and Medicinal Chemistry Letters*, **1996**, 6, 2559-2564	2.9	25
15	Resiniferatoxin-amide and analogues as ligands for protein kinase C and vanilloid receptors and determination of their biological activities as vanilloids. *Journal of Neurochemistry*, **1995**, 65, 301-18	6	21
14	Conformational changes of small molecules binding to proteins. *Bioorganic and Medicinal Chemistry* , **1995**, 3, 411-28	3.4	215

13	Residues in the second cysteine-rich region of protein kinase C delta relevant to phorbol ester binding as revealed by site-directed mutagenesis. *Journal of Biological Chemistry*, **1995**, 270, 21852-9	5.4	128
12	Conformationally constrained analogues of diacylglycerol. 6. Changes in PK-C binding affinity for 3-O-acyl-2-deoxy-L-ribonolactones bearing different acyl chains.. *Bioorganic and Medicinal Chemistry Letters*, **1994**, 4, 355-360	2.9	11
11	Prediction of geometries and interaction energies of complexes formed by small molecules using semiempirical and ab initio methods. *Computational and Theoretical Chemistry*, **1994**, 309, 279-294		10
10	Computer Automated log P Calculations Based on an Extended Group Contribution Approach. *Journal of Chemical Information and Computer Sciences*, **1994**, 34, 752-781		230
9	The discovery of novel, structurally diverse protein kinase C agonists through computer 3D-database pharmacophore search. Molecular modeling studies. *Journal of Medicinal Chemistry*, **1994**, 37, 4479-89	8.3	71
8	Graph theory and group contributions in the estimation of boiling points. *Journal of Chemical Information and Computer Sciences*, **1994**, 34, 1242-50		18
7	National Cancer Institute Drug Information System 3D database. *Journal of Chemical Information and Computer Sciences*, **1994**, 34, 1219-24		128
6	Protein kinase C. Modeling of the binding site and prediction of binding constants. *Journal of Medicinal Chemistry*, **1994**, 37, 1326-38	8.3	34
5	Applications of computers to toxicological research. *Chemical Research in Toxicology*, **1993**, 6, 748-53	4	12
4	Anti- Mycobacterium avium Activity of Quinolones: In Vitro Activities. *Antimicrobial Agents and Chemotherapy*, **1993**, 37, 2766-2766	5.9	
3	Estimation of aqueous solubility of organic molecules by the group contribution approach. Application to the study of biodegradation. *Journal of Chemical Information and Modeling*, **1992**, 32, 474-82	6.1	125
2	A computer automated structure evaluation (CASE) approach to calculation of partition coefficient. *Journal of Computational Chemistry*, **1991**, 12, 1025-1032	3.5	67
1	Basic Principles and Practices of Computer-Aided Drug Design259-278		